Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADMP Adamis Pharmaceuticals		$1.28	$0.75 ▼ $26.18	$7.26M	1.27	811,695 shs	119,800 shs
ITRM Iterum Therapeutics	$0.94 -3.7%	$0.98	$0.81 ▼ $3.02	$37.52M	2.79	1.08 million shs	666,750 shs
MACK Merrimack Pharmaceuticals	$15.13	$14.82	$11.53 ▼ $15.89	$223.77M	1.45	396,929 shs	N/A
PXSLY Pharmaxis	$0.88	$0.88	$0.62 ▼ $1.47	$26.53M	1.22	1,000 shs	N/A

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADMP Adamis Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
ITRM Iterum Therapeutics	+1.03%	-9.26%	0.00%	-9.26%	-24.03%
MACK Merrimack Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
PXSLY Pharmaxis	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADMP Adamis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ITRM Iterum Therapeutics	2.092 of 5 stars	3.5	3.0	0.0	0.0	3.3	0.0	0.0
MACK Merrimack Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PXSLY Pharmaxis	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADMP Adamis Pharmaceuticals	0.00	N/A	N/A	N/A
ITRM Iterum Therapeutics	3.00	Buy	$9.00	853.39% Upside
MACK Merrimack Pharmaceuticals	0.00	N/A	N/A	N/A
PXSLY Pharmaxis	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest MACK, ADMP, PXSLY, and ITRM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
5/8/2025	ITRM Iterum Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$9.00

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADMP Adamis Pharmaceuticals	$4.76M	0.00	N/A	N/A	($1.26) per share	0.00
ITRM Iterum Therapeutics	N/A	N/A	N/A	N/A	($0.15) per share	N/A
MACK Merrimack Pharmaceuticals	N/A	N/A	N/A	N/A	$1.31 per share	N/A
PXSLY Pharmaxis	$8.75M	3.03	N/A	N/A	$0.04 per share	22.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADMP Adamis Pharmaceuticals	-$26.48M	N/A	0.00	N/A	N/A	-502.73%	-420.53%	-256.87%	N/A
ITRM Iterum Therapeutics	-$24.77M	-$0.99	N/A	∞	N/A	N/A	N/A	-71.37%	8/13/2025 (Estimated)
MACK Merrimack Pharmaceuticals	-$1.18M	$13.87	1.09	∞	N/A	N/A	-1.93%	-1.78%	N/A
PXSLY Pharmaxis	-$9.36M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest MACK, ADMP, PXSLY, and ITRM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/13/2025	Q2 2025	ITRM Iterum Therapeutics	-$0.13	N/A	N/A	N/A	N/A	N/A
5/13/2025	Q1 2025	ITRM Iterum Therapeutics	-$0.14	-$0.14	N/A	-$0.14	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADMP Adamis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ITRM Iterum Therapeutics	N/A	N/A	N/A	N/A	N/A
MACK Merrimack Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PXSLY Pharmaxis	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADMP Adamis Pharmaceuticals	N/A	0.23	0.19
ITRM Iterum Therapeutics	N/A	3.72	3.58
MACK Merrimack Pharmaceuticals	N/A	10.78	10.78
PXSLY Pharmaxis	2.82	3.31	2.92

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADMP Adamis Pharmaceuticals	38.55%
ITRM Iterum Therapeutics	9.21%
MACK Merrimack Pharmaceuticals	63.97%
PXSLY Pharmaxis	N/A

Insider Ownership

Company	Insider Ownership
ADMP Adamis Pharmaceuticals	1.30%
ITRM Iterum Therapeutics	9.20%
MACK Merrimack Pharmaceuticals	30.57%
PXSLY Pharmaxis	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADMP Adamis Pharmaceuticals	11	9.36 million	9.24 million	Optionable
ITRM Iterum Therapeutics	10	40.00 million	36.32 million	Not Optionable
MACK Merrimack Pharmaceuticals	426	14.79 million	10.27 million	Optionable
PXSLY Pharmaxis	69	30.15 million	N/A	Not Optionable

MACK, ADMP, PXSLY, and ITRM Headlines

Recent News About These Companies

Syntara’s Amsulostat Receives WHO INN Recognition, Boosting Myelofibrosis Treatment Prospects

July 7, 2025 | tipranks.com

Syntara’s SNT-5505 Receives FDA Fast Track Designation for Myelofibrosis Treatment

June 9, 2025 | tipranks.com

Pharmaxis Ltd Highlights Uncertainties in Syntara’s Future Projections

May 6, 2025 | tipranks.com

Pharmaxis Ltd March Quarter Shareholder Update

April 30, 2025 | tipranks.com

Syntara’s SNT-6302 Shows Promising Results in Scar Treatment Trial

February 17, 2025 | tipranks.com

Pharmaxis Ltd General Meeting Addresses Key Resolutions

February 16, 2025 | tipranks.com

Pharmaxis Ltd Reveals Interim Results at Hematology Forum

February 3, 2025 | tipranks.com

Syntara Reports Promising Interim Results for Myelofibrosis Treatment

January 28, 2025 | tipranks.com

Pharmaxis Ltd Announces New Equity Raising Initiative

December 11, 2024 | tipranks.com

Syntara Prepares to Unveil Promising Myelofibrosis Data

December 9, 2024 | tipranks.com

Pharmaxis Ltd Director Increases Stock Options

November 28, 2024 | tipranks.com

Pharmaxis Ltd: A Powerhouse of Pharmaceutical Expertise

November 27, 2024 | tipranks.com

Proactive news headlines including Aurumin, PolarX, Valor Resources and Hartshead Resources

October 5, 2021 | feeds.benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MACK, ADMP, PXSLY, and ITRM Company Descriptions

Adamis Pharmaceuticals NASDAQ:ADMP

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company is headquartered in San Diego, California.

Iterum Therapeutics NASDAQ:ITRM

$0.94 -0.04 (-3.67%)

As of 10:23 AM Eastern

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

Merrimack Pharmaceuticals NASDAQ:MACK

Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company in the United States. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

Pharmaxis OTCMKTS:PXSLY

$0.88 0.00 (0.00%)

As of 06/8/2021

Pharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide. The company operates through two segments, Mannitol business, and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, an airways inflammation test that is used to identify twitchy or hyper-responsive airways, as well as to assist in diagnosing and managing asthma. The company's product pipeline consists of amine oxidase inhibitors comprising semicarbazide-sensitive amine oxidase for diabetic retinopathy; selective lysyl oxidase like inhibitors targeting chronic fibrotic diseases, such as NASH, pulmonary fibrosis, kidney fibrosis, and cardiac fibrosis; and pan-lysyl oxidase inhibitors targeting severe fibrotic indications, which includes cancers and scarring. It is also developing Orbital, a dry powder inhaler to deliver high drug doses to lungs. Pharmaxis Ltd was founded in 1998 and is headquartered in Frenchs Forest, Australia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time